Kintai, Studying The Enteric Signaling Pathway, Is Looking For Partners
Emerging Company Profile: The start-up, funded by Flagship Pioneering, is developing small molecules across multiple therapeutic areas, based on a discovery platform exploring the microbiome, gut immune system and enteric nervous system.
You may also be interested in...
Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.
Small-to-medium-sized companies launching their first or one of their only commercial products faced a particular difficult time during the pandemic. In the second quarter earnings calls, some of these SMEs are seeing momentum as the most serious COVID headwinds resolve but others are contending with ongoing challenges. [Check back tomorrow for Part 2 on companies experiencing continuing challenges.]
Thyroid eye disease drug Tepezza is now expected to generate more than $1.55bn in full year sales, despite missing a full quarter of revenue.